Extended bronchodilator treatment in chronic obstructive pulmonary disease

S. I. Rennard

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The reversibility of airflow is usually a defining characteristic of asthma, but not the other forms of chronic obstructive pulmonary disease (COPD), emphysema and bronchitis. However, airflow obstruction associated with COPD may be partially reversible, and many individuals with COPD will show an improvement in airflow following inhalation of either β-agonists or anticholinergics. Furthermore, patients who fail to respond to β-agonists may still have improved airflow following therapy with anticholinergics. As airflow can be improved in patients with COPD with the use of bronchodilators, this form of therapy has become a clinical mainstay in the management of COPD. Nevertheless, a number of questions regarding the use of bronchodilators in COPD remain. This report assesses current bronchodilator therapy.

Original languageEnglish (US)
Pages (from-to)282-285
Number of pages4
JournalEuropean Respiratory Review
Volume6
Issue number39
StatePublished - Dec 1 1996

Fingerprint

Bronchodilator Agents
Chronic Obstructive Pulmonary Disease
Cholinergic Antagonists
Therapeutics
Pulmonary Emphysema
Bronchitis
Inhalation
Asthma

Keywords

  • Bronchodilators
  • Ipratropium bromide
  • Smoking
  • β-agonists

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Extended bronchodilator treatment in chronic obstructive pulmonary disease. / Rennard, S. I.

In: European Respiratory Review, Vol. 6, No. 39, 01.12.1996, p. 282-285.

Research output: Contribution to journalArticle

@article{b62f8d9b18764ff289a68c3b59eba9a5,
title = "Extended bronchodilator treatment in chronic obstructive pulmonary disease",
abstract = "The reversibility of airflow is usually a defining characteristic of asthma, but not the other forms of chronic obstructive pulmonary disease (COPD), emphysema and bronchitis. However, airflow obstruction associated with COPD may be partially reversible, and many individuals with COPD will show an improvement in airflow following inhalation of either β-agonists or anticholinergics. Furthermore, patients who fail to respond to β-agonists may still have improved airflow following therapy with anticholinergics. As airflow can be improved in patients with COPD with the use of bronchodilators, this form of therapy has become a clinical mainstay in the management of COPD. Nevertheless, a number of questions regarding the use of bronchodilators in COPD remain. This report assesses current bronchodilator therapy.",
keywords = "Bronchodilators, Ipratropium bromide, Smoking, β-agonists",
author = "Rennard, {S. I.}",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "6",
pages = "282--285",
journal = "European Respiratory Review",
issn = "0905-9180",
publisher = "European Respiratory Society",
number = "39",

}

TY - JOUR

T1 - Extended bronchodilator treatment in chronic obstructive pulmonary disease

AU - Rennard, S. I.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - The reversibility of airflow is usually a defining characteristic of asthma, but not the other forms of chronic obstructive pulmonary disease (COPD), emphysema and bronchitis. However, airflow obstruction associated with COPD may be partially reversible, and many individuals with COPD will show an improvement in airflow following inhalation of either β-agonists or anticholinergics. Furthermore, patients who fail to respond to β-agonists may still have improved airflow following therapy with anticholinergics. As airflow can be improved in patients with COPD with the use of bronchodilators, this form of therapy has become a clinical mainstay in the management of COPD. Nevertheless, a number of questions regarding the use of bronchodilators in COPD remain. This report assesses current bronchodilator therapy.

AB - The reversibility of airflow is usually a defining characteristic of asthma, but not the other forms of chronic obstructive pulmonary disease (COPD), emphysema and bronchitis. However, airflow obstruction associated with COPD may be partially reversible, and many individuals with COPD will show an improvement in airflow following inhalation of either β-agonists or anticholinergics. Furthermore, patients who fail to respond to β-agonists may still have improved airflow following therapy with anticholinergics. As airflow can be improved in patients with COPD with the use of bronchodilators, this form of therapy has become a clinical mainstay in the management of COPD. Nevertheless, a number of questions regarding the use of bronchodilators in COPD remain. This report assesses current bronchodilator therapy.

KW - Bronchodilators

KW - Ipratropium bromide

KW - Smoking

KW - β-agonists

UR - http://www.scopus.com/inward/record.url?scp=0030455339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030455339&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030455339

VL - 6

SP - 282

EP - 285

JO - European Respiratory Review

JF - European Respiratory Review

SN - 0905-9180

IS - 39

ER -